Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

Abroad (travel likely)RecruitingPHASE2

Conditions

Immune Thrombocytopenia (ITP)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

East Carolina University, Greenville, North Carolina, United States
Contact: Study coordinator (Sue Ann Joyner Joyner) · joynersu@ecu.edu · 252-744-9010

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Immune Thrombocytopenia

Abroad (travel likely)RecruitingPHASE2

Glendale, United States · Los Angeles, United States

Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia · Treatment

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bengbu, China · Beijing, China

Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia · Treatment

Abroad (travel likely)RecruitingPHASE2

Tianjin, China